Table 1 Clinical characteristics of patients

Age (years)

65 [62–79]

Male sex (%)

8 (67)

BMI (kg/m²)

22.1 ± 4.3

Histology (clear cell carcinoma/chromophobe renal cell carcinoma), n (%)

11 (92)/1 (8)

Radical nephrectomy, n (%)

9 (75)

Course of ICI therapy, n (%)

 2

1 (8.3)

 3

4 (33.3)

 4

7 (58.3)

Duration (days) from the initial ICI therapy to the onset of symptoms

82.5 [67–100]

 Symptoms at onset, n (%)

 Fatigue

8 (66.7)

 Loss of appetite

5 (41.7)

 Lightheadedness/hypotension

3 (25)

 Nausea/vomiting

3 (25)

 Weight loss

2 (16.7)

 Weakness

2 (16.7)

 Joint pain

1 (8.3)

 Muscle pain

1 (8.3)

 Adrenal crisis

1 (8.3)

GTCAE grade, n (%)

 1

1 (8.3)

 2

5 (41.7)

 3

5 (41.7)

 4

1 (8.3)

Pituitary enlargement, n (%)

1 (8.3)

Type of hypopituitarism, n (%)

 Hypophysitis

1 (8.3)

 Isolated ACTH deficiency

11 (91.7)

Other irAEs, n (%)

 Thyroiditis (hypothyroidism)

5 (41.7)

 Hepatitis

2 (16.7)

 Another pituitary hormone deficiency

1 (8.3)

 Colitis

1 (8.3)

 Pneumonitis

1 (8.3)

 Myocarditis

1 (8.3)

 Fulminant-type 1 diabetes

1 (8.3)

 Positivity for antithyroid Abs, n (%)

4 (33.3)